GSK’s $3.3 Billion Acquisition of Affinivax

Davis Polk advised GSK plc on the deal.

GSK plc announced its acquisition of Affinivax, Inc. for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. The transaction, which is expected to close in the third quarter of 2022, is subject to customary closing conditions, including the expiration or early termination of the waiting period under the Hart-Scott- Rodino Anti-Trust Improvements Act of 1976.

GSK is a science-led global healthcare company with a special purpose to improve the quality of human life by helping people do more, feel better and live longer. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.

The Davis Polk corporate team included partners William J. Chudd (Picture) and Daniel Brass and associates Lisa Ogust and Ryan Olson. Partner David R. Bauer and associate David A. Frey provided intellectual property advice. Partner Jennifer S. Conway and associate Kerri Thompson are providing executive compensation advice. Counsel Elina Khodorkovsky provided tax advice. 

Involved fees earner: David Bauer – Davis Polk & Wardwell; Daniel Brass – Davis Polk & Wardwell; William Chudd – Davis Polk & Wardwell; Jennifer Conway – Davis Polk & Wardwell; David Frey – Davis Polk & Wardwell; Elina Khodorkovsky – Davis Polk & Wardwell; Lisa Ogust – Davis Polk & Wardwell; Ryan Olson – Davis Polk & Wardwell; Kerri Thompson – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: GlaxoSmithKline plc;